. In this large clinical trial, ipratropium bromide improved lung function while it was used, corroborating other evidence that it is an effective bronchodilator in COPD. [3] [4] [5] There are now three main classes of bronchodilators available for the treatment of COPD, each with specific clinical benefits: an anticholinergic (ipratropium bromide), A-agonists (eg, albuterol), and methylxanthines (theophylline). The preferred route of administration for bronchodilator therapy is by inhalation using a metered-dose inhaler (MDI). The MDI allows for direct delivery of drug into the lungs, thus minimizing systemic side effects. Self acute exacerbations. The limitations of 3-adrenergic use in the older population with COPD are suggested by their agonist mechanism of action, particularly their potential to cause cardiac side effects. Recently, there has been some evidence that long-term use of f-agonists may contribute to hyperreactivity,13"14 related perhaps to the aerosol itself or to the uncontrolled development of underlying inflammation.
The introduction of inhaled ipratropium bromide, a quaternary amine anticholinergic, has added flexibility to bronchodilator therapy in COPD. A study by Braun et ipratropium-albuterol therapy; in many patients, a more logical third step may be to switch from combination aerosol to a combination of the inhalation solutions of the two drugs.
Not long ago, theophylline preparations were the mainstay of COPD treatment. Theophylline is a potent bronchodilator in COPD and has an advantage over the MDIs in the ease of oral administration. But theophylline also has a narrow therapeutic index. Theophylline preparations can be more difficult to prescribe than inhalers because of their known interactions with other drugs and because of alterations in theophylline metabolism in patients with hepatic or cardiac diseases. Long-acting theophylline preparations are useful for reducing nocturnal symptoms. This class of bronchodilators may have additional beneficial effects on respiratory muscle performance and central respiratory drive.7 '22 The use of corticosteroids in the management of COPD has still not been completely clarified.7 A 4-year study by Dompeling et If patients do not respond adequately to combination aerosol therapy, the attending physician has two options. One is to switch to a combination of the ipratropium and albuterol solutions. This regimen improves bronchodilation by delivering higher doses of the drugs than can be safely accomplished with MDIs; the higher dose of ipratropium also favors more prolonged effect. The two solutions can be mixed conveniently, and nebulizer therapy may be easier for many patients to self-administer than MDI therapy. An alternative to switching to combination solution would be to add a long-acting theophylline preparation to the combination MDI. Some patients may find this simpler and more convenient than using a nebulizer. Such a regimen, however, does require careful monitoring of serum theophylline levels, and may increase the side effects of drug therapy. Following the algorithm as described, theophylline may also be added to combination nebulizer therapy with the ipratropium and albuterol solutions.
Since corticosteroids are effective in some patients with COPD, particularly those with an inflammatory component to their disease, these drugs should be kept in mind by the clinician. Use of corticosteroids should be carefully monitored. If a positive response is obtained, the dose should be titrated down to minimize side effects. Oral corticosteroids are a useful option in patients who have difficulty administering aerosols.
CONCLUSION
The growing realization in recent years that airways obstruction in patients with COPD can be significantly relieved with the use of bronchodilators has changed the clinical approach to treating this disease. As demonstrated by the Lung Health Study, the physician's first priority is to encourage all patients who smoke to stop. If significant airways obstruction persists, stepped-care implementation of bronchodilator therapy is indicated. The current treatment algorithm begins with inhaled ipratropium, which can be successfully supplemented with 3-agonists and theophylline. Cautious use of corticosteroids may also be beneficial.
